Gelteq Limited (NASDAQ:GELS – Get Free Report) saw a significant decline in short interest in the month of July. As of July 15th, there was short interest totaling 112,420 shares, a decline of 32.9% from the June 30th total of 167,463 shares. Currently, 1.0% of the company’s shares are short sold. Based on an average daily volume of 41,384 shares, the short-interest ratio is presently 2.7 days.
Institutional Trading of Gelteq
A hedge fund recently bought a new stake in Gelteq stock. Susquehanna International Group LLP bought a new stake in Gelteq Limited (NASDAQ:GELS – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 41,550 shares of the company’s stock, valued at approximately $57,000. Susquehanna International Group LLP owned approximately 0.44% of Gelteq as of its most recent SEC filing.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings lowered Gelteq from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, June 26th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Gelteq currently has an average rating of “Sell”.
Gelteq Price Performance
Gelteq stock opened at $0.55 on Friday. Gelteq has a fifty-two week low of $0.39 and a fifty-two week high of $2.02. The firm’s 50 day simple moving average is $0.65 and its 200-day simple moving average is $0.71.
Gelteq (NASDAQ:GELS – Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported ($0.12) EPS for the quarter.
Gelteq Company Profile
Gelteq Inc is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc is based in NEW YORK.
Featured Stories
- Five stocks we like better than Gelteq
- Quantum Earnings Could Decide Whether the Sector’s Sell-Off Has Gone Too Far
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
Receive News & Ratings for Gelteq Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gelteq and related companies with MarketBeat.com's FREE daily email newsletter.
